NCT06809712View on ClinicalTrials.gov

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Hematologic Disease
Interventions
DRUG

Busulfan (Busulfex)

Myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d); Reduced intensity conditioning: Busulfan (Bu，3.2 mg/kg/d IV -7d\~-5d);

DRUG

Cyclophosphamide (CTX)

Myeloablative conditioning: Cyclophosphamide (Cy，1.8g/m2, -5d, -4d) Cyclophosphamide is not used for reduced intensity conditioning

DRUG

Fludarabine (Fludara)

Myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d); Reduced intensity conditioning: Fludarabine (Flu，30mg/m2 /d IV -10d\~-5d);

DRUG

Semustine (MeccNU)

"For both myeloablative and reduced intensity conditioning:~Semustine (MeCCNU: 250 mg/m2 orally-3d)"

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

He Huang

OTHER